Cargando…

Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study

SIMPLE SUMMARY: Mogamulizumab is a recent monoclonal antibody prescribed in the second line to treat advanced mycosis fungoides and Sézary syndromes. We collected data from all patients who used mogamulizumab in six French university hospitals until 1 September 2021. Our primary objective was to det...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jouandet, Marie, Nakouri, Inès, Nadin, Lawrence, Kieny, Alice, Samimi, Mahtab, Adamski, Henri, Quéreux, Gaëlle, Chaby, Guillaume, Dompmartin, Anne, L’Orphelin, Jean-Matthieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996883/ https://www.ncbi.nlm.nih.gov/pubmed/35406431 http://dx.doi.org/10.3390/cancers14071659

Ejemplares similares

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2021)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
por: Bailly-Caillé, Barbara, et al.
Publicado: (2023)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
por: Croix, Manuel, et al.
Publicado: (2023)

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
por: Caruso, Laura, et al.
Publicado: (2022)

Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023)

Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIV
por: Boisclair, Stephanie, et al.
Publicado: (2022)

Alopecia areata after mogamulizumab treatment
por: Raval, Neel S., et al.
Publicado: (2021)

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
por: Horwitz, Steven, et al.
Publicado: (2021)

A novel mouse model of cutaneous T‐cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy
por: Nakahashi, Keiko, et al.
Publicado: (2022)

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Cutaneous adverse reactions and anti-tumor effects of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma
por: Yonekura, Kentro, et al.
Publicado: (2015)

Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab
por: Westergaard, Sarah A., et al.
Publicado: (2020)

Alopecia areata-like presentations with mogamulizumab therapy
por: Kincaid, Colin M., et al.
Publicado: (2023)

Mogamulizumab Treatment in a Hemodialysis Patient with Adult T-Cell Leukemia/Lymphoma
por: Yoshihara, Mari, et al.
Publicado: (2014)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care
por: Hawkins, Neil, et al.
Publicado: (2023)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab
por: Wang, Lan, et al.
Publicado: (2020)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
por: Hirosawa, Makoto, et al.
Publicado: (2022)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
por: Trum, Nicholas A., et al.
Publicado: (2021)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
por: Lama, Carine M., et al.
Publicado: (2023)

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
por: Phillips, Adrienne A., et al.
Publicado: (2019)

Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-Cell lymphoma
por: Asokan, Ishan, et al.
Publicado: (2021)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018)

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
por: Musiek, Amy C. M., et al.
Publicado: (2021)

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review
por: TRAGER, Megan H., et al.
Publicado: (2020)

Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma
por: Bagot, Martine, et al.
Publicado: (2022)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
por: Ishida, Takashi, et al.
Publicado: (2017)

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022)

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vac1fb9ilkem856jthbn7harle